MetLife Investment Management LLC Purchases 1,394 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

MetLife Investment Management LLC raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 30,822 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,394 shares during the period. MetLife Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $1,115,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $52,000. Headlands Technologies LLC increased its position in shares of Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,015 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $72,000. Finally, Venturi Wealth Management LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $92,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 17th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 0.1 %

NASDAQ:SUPN opened at $32.45 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 30.33 and a beta of 0.90. The stock’s 50 day moving average price is $31.86 and its two-hundred day moving average price is $34.97.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.30% of the stock is owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.